Kathleen Angkustsiri, M.D.

Transcription

1 Kathleen Angkustsiri, M.D. Kathleen Angkustsiri, M.D., Assistant Professor of Clinical Pediatrics, Section of Developmental Behavioral Pediatrics, School of Medicine Education B.A., Psychology/Human Biology, Stanford University, 1998 M.D., New York University School of Medicine, 2003 Residency, Children s Hospital and Research Center at Oakland, 2006 Fellowship, University of California Davis Medical Center, 2009 Biography Dr. Kathleen Angkustsiri is a developmental-behavioral pediatrician with interests in neurodevelopmental disorders including autism spectrum disorders, chromosome 22q11.2 deletion syndrome (22q11.2DS), and fragile X syndrome. She completed her B.A. in Psychology and Human Biology at Stanford University and received her M.D. from New York University School of Medicine. Dr. Angkustsiri trained in Pediatrics at Children s Hospital and Research Center in Oakland, and she completed her fellowship in Developmental-Behavioral Pediatrics at the University of California, Davis in She is involved in research on dysmorphology in children with autism spectrum disorders, behavioral characteristics of children with 22q11.2DS, and clinical trials. Publications Angkustsiri K and Simon TJ: Chromosome 22q11.2 Deletion Syndrome, Hansen RL, (ed) (2012), APPI Clinical Manual of Neurodevelopmental Disorders, American Psychiatric Publishing. ** IN PRESS ** Angkustsiri K and Hansen RL: Autism Spectrum Disorders, Elzouki AY, Stapleton FB, Whitley RJ, Oh W, Harfi HA, Nazer H, (ed) (2012), Textbook of Clinical Pediatrics (2nd edition), Springer, New York. Angkustsiri K, Krakowiak P, Moghaddam B, Wardinsky T, Gardner J, Kalamkarian N, Hertz- Picciotto I, Hansen RL (2011). Minor Physical Anomalies in Children with Autism Spectrum Disorders. Autism, 15(6), Akins S, Angkustsiri K, Hansen RL (2010). Complementary and Alternative Medicine in Autism: An Evidence-Based Approach to Negotiating Safe and Efficacious Interventions with Families. Neurotherapeutics, 7, Hansen RL, Ozonoff S, Krakowiak P, Angkustsiri K, Jones C, Deprey LJ, Le DN, Croen LA, Hertz-Picciotto I (2008). Regression in autism: prevalence and associated factors in the CHARGE Study. Ambul Pediatr, 8(1), Angkustsiri K, Wirojanan J, Deprey LJ, Gane LW, Hagerman RJ (2008). Fragile X syndrome with anxiety disorder and exceptional verbal intelligence. Am J Med Genet A, 146(3),

2 Wirojanan J, Kraff J, Hawkins DS, Laird C, Gane LW, Angkustsiri K, Tassone F, Hagerman RJ (2008). Two boys with fragile x syndrome and hepatic tumors. J Pediatr Hematol Oncol, 30(3), Wirojanan J, Angkustsiri K, Tassone F, Gane LW, Hagerman RJ (2008). A girl with fragile X premutation from sperm donation. Am J Med Genet A, 146(7), Perry R, Gilbert EM, Angkustsiri K. Jensen PS (2000). Are Stimulants Overprescribed? [Comment: Letter]. Journal of the American Academy of Child & Adolescent Psychiatry, 39(3): Coleman AE, Angkustsiri K, Janz S (1999). Use of B1-repeat-supplemented Cot-1 DNA to enhance background suppression in FISH [Technical Tips]. Elsevier Trends Journals Technical Tips Online, 1(72), T Presentations Camilleri K, Angkustsiri K, Nordahl CW, Lee A, Boyd S, Amaral DG (2011). Orbital distances do not correlate to cerebellar volume in children with autism spectrum disorders. Oral Presentation at the Western Society for Pediatric Research/Western Student Medical Research Forum. Angkustsiri K, Leckliter I, Enriquez J, Beaton E, Hansen RL, Simon TJ (2011). Sensory Processing Differences are Related to Panic/Agoraphobia symptoms in children with Chromosome 22q11.2 Deletion Syndrome/VCFS. Poster Presentation at the Pediatric Academic Societies Annual Meeting. Angkustsiri K, Leckliter I, Enriquez J, Beaton EA, Hansen RL, Simon TJ (2010). Anxiety, but not intelligence, predicts adaptive functioning in children with chromosome 22q11.2 deletion syndrome. Poster Presentation at the Society for Developmental-Behavioral Pediatrics Annual Meeting. Angkustsiri K, Leckliter I, Beaton EA, Stoddard J, Hansen RL, Simon TJ (2010). Anxiety, not intelligence, predicts adaptive functioning in children with VCFS/22q11.2DS. Oral Presentation at the Velocardiofacial Syndrome Educational Foundation Annual Meeting. Angkustsiri K., Stoddard J., Leckliter I., Enriquez J., Beaton, E.A., Hansen, R.L., Simon, T.J (2010). COMT genotype, Anxiety, and Hyperactivity in Chromosome 22q11.2 Deletion Syndrome. Platform Presentation at the Pediatric Academic Societies Annual Meeting. Angkustsiri K, Akins RS, Leckliter I, Enriquez J, Stoddard J, Hansen RL, Simon TJ (2010). Chromosome 22q11.2 Deletion Syndrome Translational Clinic. Oral Presentation at the Western Society for Pediatric Research Regional Meeting. Angkustsiri K, Leckliter I, Enriquez J, Akins R, Stoddard J, Hansen R, Simon TJ (2009). Chromosome 22q11.2 Deletion Syndrome: Integrating Clinical and Research Experience. Poster Presentation at the Association of University Centers on Disabilities Annual Meeting and Conference. Angkustsiri K (2009). Gene-Environment Interactions, Guatemala Fragile X and Autism Conference, Guatemala City, Guatemala. 2

3 Angkustsiri K (2009). New Research in Autism, Guatemala Fragile X and Autism Conference, Guatemala City, Guatemala. Angkustsiri K, Camilleri K, Cochran L, Wu-Nordahl C, Barnett L, Hansen RL, Mastergeorge A, Rogers S, Boyd S (2009). Poor Verbal and Non-Verbal Skills in Children with Abnormal Craniofacial Variability Indices (CVI) and ASD. Oral Presentation at the International Meeting for Autism Research. Angkustsiri K (2009). Anxiety and Attentional Symptoms in Children with Chromosome 22q11.2 Deletion Syndrome, Research Colloquium, Department of Pediatrics, UC Davis, Sacramento, CA, May Angkustsiri K (2009). Three Dimensional Evaluation of Facial Structures in Autism Spectrum Disorders, Grand Rounds, Department of Pediatrics, UC Davis, Sacramento, CA. Angkustsiri K (2009). Pharmacological and Complementary Treatments in Autism Spectrum Disorders, Innovative Research In Autism (IRIA) Conference, Tours, France. Angkustsiri K (2009). Environmental Contributions to Autism Risk, Pediatric Academic Societies Annual Meeting, Baltimore, MD. Angkustsiri K (2009). Mental Health Module for Social Workers, Sierra Adoption Services, Sacramento, CA. Angkustsiri K, Tartaglia N, Johnson J, Enriquez J, Hansen RL, Simon TJ (2009). Underidentification of Anxiety and Attentional Symptoms in Children with Chromosome 22q11.2 Deletion Syndrome, Western Society for Pediatric Research (WSPR) Regional Meeting, Carmel, CA. Research Funding Principal Investigator: Biological Predictors of Functional Outcome in Children with 22q11.2 Deletion Syndrome, Children's Miracle Network, 7/1/10-6/30/12, $30,597. This is a crosssectional study of cognitive and adaptive functioning, behavioral/mental health symptoms, and medical/biological measures of children with 22q11.2DS. This study investigates the factors that contribute to positive functional outcomes in these children as measured by their adaptive functioning or everyday life skills. Co-Investigator: 22q11.2 Deletion Syndrome Translational Clinic, Tony J. Simon, Ph.D. (Principal Investigator), Dempster Family Foundation, 11/ /2012, $20,000 annually. This project provides multidisciplinary assessment of cognition and behavior of children with 22q11.2DS and provides verbal feedback and an associated written report with an interpretation of the research evaluation and recommendations to guide parents, educators, and health care professionals. Co-Investigator: Interdisciplinary Investigation of Biological Signatures of Autism Subtypes, David Amaral (Principal Investigator), NIH/NIMH, 10/1/09-9/30/11, $1,498,374. The overall goal of this interdisciplinary project is to identify different subtypes of autism based on behavioral, biochemical, and brain imaging markers. Assistant Researcher: The CHARGE Study: Childhood Autism Risks from Genetics and the Environment, Irva Hertz-Picciotto (Principal Investigator), NIH/NIEHS, 1/1/07-12/31/11 3

4 Assistant Researcher, UC Davis Center of Excellence in Development Disabilities, Robin Hansen (Principal Investigator), DHHS Administration for Children and Families, 7/1/06-6/30/11, $1,000,000. This project will continue an epidemiologic study of the environmental and genetic causes of autism that was initiated under the UC Davis Center for Children s Environmental Health (CCEH) funded in the fall of 2001 by the NIEHS (1 P01 ES11269), U.S. EPA, and MIND (Medical Investigations of Neurodevelopmental Disorders) Institute. The CHARGE Study is a comprehensive, population-based case-control investigation of underlying causes for autism and triggers of regression. Co-Investigator: Early Exposure to Acetaminophen and Autism, Irva Hertz-Picciotto (Principal Investigator), Autism Speaks, 6/1/10-5/31/11, $19,997. The proposed project will serve as a pilot study to assess feasibility of conducting a full investigation of whether intake of acetaminophen or other analgesics in early childhood is a risk factor for autism/asd. Co-Investigator: Defining the Underlying Biology of Gastrointestinal Dysfunction in Children and Adolescents with ASD, Paul Ashwood (Principal Investigator), Autism Speaks, 4/15/11-4/14/13. $769,943. This project studies the potential mechanisms influencing GI dysfunction in autism. We will comprehensively evaluate the microbiota, metabolic and immune profiles in a well-characterized cohort of children with autism, with irregular bowel movements, and compare them to children with autism without irregular bowel movements and typically developing controls with or without irregular bowel movements. Co-Investigator: A Single Dose, Open-Label Study Evaluating the Pharmacokinetics of an Oral Mematine HCl Modified-Release Formulation in Pediatric Patients with Autistic Spectrum Disorders, Randi Hagerman (Principal Investigator), Forest Research Laboratories, 06/30/ Co-Investigator: An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism, Randi Hagerman (Principal Investigator), Forest Research Laboratories, Co-Investigator: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Randi Hagerman (Principal Investigator), Forest Research Laboratories, Co-Investigator: A Phase III Randomized Double Blind Placebo Controlled Trial of LUMINENZ-AT In Children with Autism, Randi Hagerman (Principal Investigator), Curemark, Co-Investigator: EARLY PHARMACOTHERAPY GUIDED BY BIOMARKERS IN AUTISM A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2-6 year old children with autistic disorder, Robin Hansen (Principal Investigator), The National Institute of Neurological Disorders and Stroke, Co-Investigator: A randomized, double-blind, placebo-controlled, pharmacokinetic, safety and tolerability, and exploratory efficacy and pharmacodynamic effects study of RO in adult patients with fragile X syndrome,

5 Co-Investigator: An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects with Fragile X Syndrome, Randi Hagerman (Principal Investigator), Seaside Therapeutics, Collaborator: Network of Excellence in Neuroscience Clinical Trials (U10), Craig McDonald (Principal Investigator), National Institute of Neurological Disorders and Stroke, 3/11/11. Community Service Medical Legal Partnership with Legal Services of Northern California and Health Rights Hotline, current Consultant and Presenter, Sierra Forever Families (formerly Sierra Adoption Services) Adoption Module, Junior Mentor, Pediatric Academic Societies New Century Scholar's Program, 2006-current MIND Institute Committee for Quality Improvement (CQI), Awards and Honors Summer Internship Program in Biomedical Research. Preceptor: Sigfried Janz, MD/PhD. Lab of Genetics, National Cancer Institute, National Institutes of Health, 1997 Western Society for Pediatric Research Carmel Scholar, 2007 Western Society for Pediatric Research Mead Johnson Travel Award, Western Association For Medical Research/Centocor Scholar,